Lyanne Harrison, an analyst from Bank of America Securities, maintained the Buy rating on Resmed. The associated price target remains the same with $300.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lyanne Harrison’s rating is based on several positive factors contributing to Resmed’s growth outlook. The company is effectively generating and capturing demand through strategic initiatives, such as addressing testing bottlenecks with recent acquisitions in home sleep testing. This approach is expected to improve CPAP device growth, supported by macro trends that favor increased patient adoption of CPAP therapy.
Additionally, Resmed’s gross margin expansion trajectory is promising, with the company reiterating its guidance for fiscal year 2026 and targeting further improvements through fiscal year 2030. The anticipated return of Philips Respironics to the US market is seen as a potential risk for smaller manufacturers, but Resmed is well-positioned to maintain its competitive edge. These factors collectively support the Buy rating, with a positive growth outlook and a price objective of 300.00 USD.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $307.00 price target.